Clinical Trial Detail

NCT ID NCT03456063
Title A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium

Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium

Age Groups: adult senior

Additional content available in CKB BOOST